胡海燕

联系方式

办公电话：020-39336530(O)

电子邮箱：lsshhy@mail.sysu.edu.cn

办公地址：广州市大学城外环东路132号 bm11222宝马娱乐网站214B室 邮编：510006

简单介绍

胡海燕，女，教授，博士生导师。中国药学会药剂学专委会委员，中国抗癌协会纳米肿瘤学专业委员会委员，中国民族医药学会布朗医药分会常务理事；Eur J Pharm Biopharm, Molecules和《药学学报》杂志编委。研究方向主要包括：1)生物被膜靶向递药系统；2)毛发健康相关递药系统；3)消化道疾病智能递药系统。以第一作者或通讯作者在J Control Release、Acta Pharm Sin B，Carbohyd Polym等发表学术论文50余篇，获得10余项中国专利授权。主持“十二五”“重大新药创制”、国家自然科学基金面上项目（5项）、广州市科技计划重点项目、广东省自然科学基金、中山大学交叉学科培育项目等课题。

教育经历

2014/11-2015/11 英国诺丁汉大学，访问学者

2008/05-2008/08 美国Huahai US Co., Ltd.，Senior Research Fellow

2003/09-2006/06 四川大学，获得药剂学博士学位；

1995/09-1998/06 华西医科大学（现四川大学），获得药剂学硕士学位

1991/09-1995/06 华西医科大学（现四川大学），获得药学学士学位

工作经历

2017/1至今 bm11222宝马娱乐网站教授

2016/4-2017/4 滇西应用技术大学傣医bm11222宝马娱乐网站副院长(挂职)

2010/1-2017/1 bm11222宝马娱乐网站副教授

1998/7-2010/1 bm11222宝马娱乐网站（系）助教、讲师

教学情况

本科生课程 药剂学实验（课程负责人）、 药剂学

研究生课程 药剂学进展（课程负责人）、改良型新药的开发与转化（课程负责人）、岗位认知（课程负责人）

社会/学术任职

《药学学报》编委

Eur J Pharm Biopharm编委

Molecules编委

中国药学会药剂学专委会委员

中国民族医药学会布朗医药分会常务理事

中国抗癌协会纳米肿瘤学专业委员会委员

科研项目

[1]国家自然科学基金面上项目：脲酶响应型非抗生素抗生物被膜联合免疫激活自组装纳米胶束的构建及清除幽门螺杆菌作用机制的研究（课题负责人，No.82273870，2023～2026年）

[2]国家自然科学基金面上项目：针对铜绿假单胞菌菌膜所致顽固性肺部感染的全过程智能递药系统的构建及其阻断细菌耐药发生的机制研究（课题负责人，No. 81973264，2020～2023年）

[3] 国家自然科学基金面上项目：仿病毒亲水富电表面介孔二氧化硅纳米粒的构建及其克服胰岛素口服吸收多重屏障的机制研究（课题负责人，No. 81773659，2018～2021年）

[4] 国家自然科学基金面上项目：靶向降解、清除幽门螺杆菌菌膜 (biofilm)的多功能脂质-聚合物杂化纳米粒的制备、作用评价及相关机制研究（课题负责人，No. 81473154，2015～2018年）

[5] 国家自然科学基金面上项目：胆固醇代谢产物Triol作为内源性神经保护因子的发现及其作用机制研究”（课题负责人，No. 81173045，2012～2015年）

[6] “十二五”国家科技重大专项“重大新药创制”：针对欧洲市场阿奇霉素制剂的研发与产业化（课题负责人，No. 2011ZX09202-101-06 ，2011～2014年）

[7] 广州市科技计划重点项目：清除幽门螺杆菌感染缓解胃黏膜损伤非抗生素制剂的研发与产业化（课题负责人，No. 2023B03J0022，2023～2026年）

[8] 广东省自然科学基金面上项目：智能吸入递药经“除膜四步曲+细菌外膜扰动+抗毒力”策略抗铜绿假单胞菌所致慢性肺部感染（课题负责人，No. 2024A1515011193，2024～2026年）

[9] 广东省自然科学基金面上项目：针对幽门螺杆菌（膜）持续感染全过程的多功能递药系统的构建及其多维度清除机制研究（课题负责人，No. 2021A1515012621，2021～2023年）

[10] 广东省自然科学基金面上项目：针对铜绿假单胞菌菌膜所致顽固性肺部感染的全过程智能递药系统的构建及其阻断细菌耐药发生的机制研究（课题负责人，No. 2019A1515011954，2019～2021年）

[11] 中山大学交叉学科培育项目：靶向H. pylori biofilm提高幽门螺杆菌清除率的多功能脂质聚合物纳米粒的研究（课题负责人，No. 18ykzd08，2018～2019年）

代表性论著

[1] M Xu#, SH Yu#, *, PY Li, YL Chen, YJ Chen, JY Pan, X Deng*, HY Hu*. Tailored multilayer nanoparticles against resistant P. aeruginosa by disrupting the thickened mucus, dense biofilm and hyperinflammation. J Control Release. 2025, 378:588-604.

[2] YL Wang#, Y Chen#, HJ Zhang, SH Yu, G  Yuan*, HY Hu*, Colon-targeted self-assembled nanoparticles loaded with berberine double salt ameliorate ulcerative colitis by improving intestinal mucosal barrier and gut microbiota. Colloid Surface B.2025, 245:114353.

[3] XF Zhang, JB Hao, TL Lu, YT Dong, YY Sun, YJ Yu, SX Li, SH Yu, HY Hu*,  Resveratrol-Loaded Versatile Nanovesicle for Alopecia Therapy via Comprehensive Strategies. Int J Nanomedicine. 2024, 19:13875-13900.

[4] JK Zhao#, SQ Hao#, Y Chen, XX Ye, PC Fang*, HY Hu*, Tauroursodeoxycholic acid liposome alleviates DSS-induced ulcerative colitis through restoring intestinal barrier and gut microbiota. Colloid Surface B. 2024, 236:113798.

[5] SH Yu, JY Pan, M. Xu, YJ Chen, PY Li*, HY Hu*, Antibacterial activity and mechanism of colistin-loaded polymeric nanoparticles for combating multidrug-resistant Pseudomonas aeruginosa biofilms: A synergistic approach. Int J Biol Macromol. 2024, 282(Pt 1):136757.

[6] YY Sun, TL Lu, JY Pan, HN He, M Xu, YY Chen, Y Chen, PC Fang, XX Ye, SX Li, HY Hu*, SH Yu*, Dual tobramycin and docosahexaenoic acid loaded nanoemulsions combating Pseudomonas aeruginosa-induced pulmonary infection. Colloid Surface B. 2024, 242:114088.

[7] SX Li, YH Huang, YY Sun, TL Lu, YT Dong, SH Yu, XF Zhang*, HY Hu*, Panax notoginseng saponins loaded W/O microemulsion for alopecia therapy with panthenol as cosurfactant to reduce skin irritation. Int J Pharmaceut. 2024, 663:124585.

[8] PY Li, JY Pan, YT Dong, YY Sun, YL Wang, K Liao, YL Chen, X Deng, SH Yu*, HY Hu*, Microenvironment responsive charge-switchable nanoparticles act on biofilm eradication and virulence inhibition for chronic lung infection treatment. J Control Release. 2024, 365: 219-235.

[9] XF Zhang, JK Zhao, SQ Hao, Q Ding, SH Yu, I.S. Mohammad, J Wang, HY Hu*, Biological activities and detoxification mechanisms of Clerodendrum chinense var. simplex, Marsdenia tenacissima and Arundina graminifolia: The Dai antidotes. Zhongshan Daxue Xuebao/Acta Scientiarum Natralium Universitatis Sunyatseni. 2023, 262: 89-99.

[10] MT Xiong#, YY Li#, HN He, SQ Hao, PC Fang, M Xu, Y Chen, YJ Chen, SH Yu*, HY Hu*, Cyclosporine A-loaded colon-targeted oral nanomicelles self-assembly by galactosylated carboxymethyl chitosan for efficient ulcerative colitis therapy. Eur J Pharm Biopharm. 2023, 189: 152-164.

[11] HH Rong#, YT Dong#, JK Zhao, XF Zhang, SX Li, YY Sun, TL Lu, SH Yu*, HY Hu*, Fetal milieu-simulating hyaluronic acid-dopamine-chondroitin sulfate hydrogel promoting angiogenesis and hair regeneration for wound healing. Int J Biol Macromol. 2023, 248:125739.

[12] YQ Zou#, XN Chen#, YY Sun, PY Li, M Xu, PC Fang, SQ Zhang, G Yuan, X Deng, HY Hu*, Antibiotics-free nanoparticles eradicate Helicobacter pylori biofilms and intracellular bacteria. J Control Release. 2022, 348: 370-385.

[13] XF Zhang, SX Li, YT Dong, HH Rong, JK Zhao, HY Hu*, A multifunctional cholesterol-free liposomal platform based on protopanaxadiol for alopecia therapy. Nano Res. 2022, 15: 9498-9510.

[14] X Yang, YL Wang, JK Zhao, HH Rong, YJ Chen, MT Xiong, XX Ye, SH Yu*, HY Hu*, Coordinated regulation of BACH1 and mitochondrial metabolism through tumor-targeted self-assembled nanoparticles for effective triple negative breast cancer combination therapy. Acta Pharm Sin B. 2022, 12: 3934-3951.

[15] YQ Rao#, YY Sun#, PY Li, M Xu, XN Chen, YL Wang, Y Chen, X Deng, SH Yu*, HY Hu*, Hypoxia-sensitive adjuvant loaded liposomes enhance the antimicrobial activity of azithromycin via phospholipase-triggered releasing for Pseudomonas aeruginosa biofilms eradication. Int J Pharmaceut.  2022, 623:121910.

[16] XN Chen, YQ Zou, SQ Zhang, PC Fang, SX Li, PY Li, YY Sun, G Yuan, HY Hu*, Multi-functional vesicles improve Helicobacter pylori eradication by a comprehensive strategy based on complex pathological microenvironment. Acta Pharm Sin B. 2022, 12: 3498-3512.

[17] Y Zhang, MT Xiong, XM Ni, JR Wang, HH Rong, YQ Su, SH Yu, I.S. Mohammad, S.S.Y. Leung, HY Hu*, Virus-Mimicking Mesoporous Silica Nanoparticles with an Electrically Neutral and Hydrophilic Surface to Improve the Oral Absorption of Insulin by Breaking through Dual Barriers of the Mucus Layer and the Intestinal Epithelium. ACS Appl. Mater. Interfaces. 2021, 13: 18077-18088.

[18] CC Lin, X Yang, HT Li, YQ Zou, I.S. Mohammad, HH Rong, YQ Rao, J Song, S.S.Y. Leung, HY Hu*, Self-assembled nanomedicine combining a berberine derivative and doxorubicin for enhanced antitumor and antimetastatic efficacy: Via mitochondrial pathways. Nanoscale. 2021, 13: 6605-6623.

[19] YN Shen, YQ Zou, XN Chen, PY Li, YQ Rao, X Yang, YY Sun, HY Hu*, Antibacterial self-assembled nanodrugs composed of berberine derivatives and rhamnolipids against Helicobacter pylori. J Control Release. 2020, 328: 575-586.

[20] YN Shen, PY Li, XN Chen, YQ Zou, HT Li, G Yuan, HY Hu*, Activity of Sodium Lauryl Sulfate, Rhamnolipids, and N-Acetylcysteine against Biofilms of Five Common Pathogens. Microb Drug Resist. 2020, 26: 290-299.

[21] XM Ni, Q Guo, YQ Zou, Y Xuan, I.S. Mohammad, Q Ding, HY Hu*, Preparation and characterization of bear bile-loaded pH sensitive in-situ gel eye drops for ocular drug delivery. Iran J Basic Med Sci. 2020, 23: 922-929.

[22] YL Wang#, HZ Huang#, HJ Zou, XY Tian, J Hu, PX Qiu, HY Hu*, GM Yan, Liposome Encapsulation of Oncolytic Virus M1 to Reduce Immunogenicity and Immune Clearance in Vivo. Mol. Pharmaceutics. 2019, 16: 779-785.

[23] J Song, CC Lin, X Yang, YQ Xie, P Hu, HT Li, WB Zhu, HY Hu*, Mitochondrial targeting nanodrugs self-assembled from 9-O-octadecyl substituted berberine derivative for cancer treatment by inducing mitochondrial apoptosis pathways. J Control Release. 2019, 294: 27-42.

[24] XW Li, MX Huang, KK Lo, WL Chen, YY He, YL Xu, HZ Zheng, HY Hu*, J Wang*, Anti-diabetic effect of a shihunine-rich extract of dendrobium loddigesii on 3t3-l1 cells and db/db mice by up-regulating AMPK–GLUT4–PPARα. Molecules. 2019, 24(14):2673.

[25] PY Li, XN Chen, YN Shen, HT Li, YQ Zou, G Yuan, P Hu, HY Hu*, Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm. J Control Release. 2019, 300: 52-63.

[26] XN Chen, PY Li, YN Shen, YQ Zou, G Yuan, HY Hu*, Rhamnolipid-involved antibiotics combinations improve the eradication of Helicobacter pylori biofilm in vitro: A comparison with conventional triple therapy. Microb Pathogenesis. 2019, 131: 112-119.

[27] XW Li, HP Chen, YY He, WL Chen, JW Chen, L Gao, HY Hu*, J  Wang*, Effects of rich-polyphenols extract of dendrobium loddigesii on anti-diabetic, anti-inflammatory, antioxidant, and gut microbiota modulation in db/db Mice. Molecules. 2018, 23(12):3245.

[28] HP Chen, XW Li, YL Xu, KK Lo, HZ Zheng, HY Hu*, J Wang*, YC Lin*, Study on the polar extracts of dendrobium nobile, D. officinale, D. loddigesii, and flickingeria fimbriata: Metabolite identification, content evaluation, and bioactivity assay. Molecules. 2018, 23(5):1185.

[29] HB Zhou, JS Chen, SY Li, JP Zhang, CE Zhu, H Ran, MH Luo, X Pan*, HY Hu*, CB Wu, Preparation of Acid-Resistant Microcapsules with Shell-Matrix Structure to Enhance Stability of Streptococcus Thermophilus IFFI 6038. J Food Sci. 2017, 82: 1978-1984.

[30] Q Xing, J Song, XH You, DL Xu, KX Wang, JQ Song, Q Guo, PY Li, CB Wu, HY Hu*, Microemulsions containing long-chain oil ethyl oleate improve the oral bioavailability of piroxicam by increasing drug solubility and lymphatic transportation simultaneously. Int J Pharmaceut. 2016, 511: 709-718.

[31] YQ Wang, LP Tang, W Yin, JS Chen, TD Leng, XK Zheng, WB Zhu, HP Zhang, PX Qiu, XX Yang, GM Yan, HY Hu*, Simultaneous determination of seven neuroactive steroids associated with depression in rat plasma and brain by high performance liquid chromatography-tandem mass spectrometry. Anal Sci. 2016, 32: 981-988.

[32] J Tuo#, YQ Xie#, J Song, YZ Chen, Q Guo, X Liu, XM Ni, DL Xu, HZ Huang, S Yin, WB Zhu, J Wu, HY Hu*, Development of a novel berberine-mediated mitochondria-targeting nano-platform for drug-resistant cancer therapy. J Mater Chem B. 2016, 4: 6856-6864.

[33] PY Li, J Song, XM Ni, Q Guo, H Wen, QY Zhou, YN Shen, YJ Huang, PX Qiu, SZ Lin, HY Hu*, Comparison in toxicity and solubilizing capacity of hydroxypropyl-β-cyclodextrin with different degree of substitution. Int J Pharmaceut. 2016, 513: 347-356.

[34] Q Guo#, J Cai#, PY Li, DL Xu, XM Ni, H Wen, D Liu, SZ Lin, HY Hu*, Comparison of bile salt/phosphatidylcholine mixed micelles in solubilization to sterols and stability. Drug Des Dev Ther. 2016, 10: 3789-3798.

[35] YL Wang, H Jiang, HZ Huang, YQ Xie, YS Zhao, XH You, LP Tang, YQ Wang, W Yin, PX Qiu, GM Yan, HY Hu*, Determination of neuroprotective oxysterols in Calculus bovis, human gallstones, and traditional Chinese medicine preparations by liquid chromatography with mass spectrometry. J Sep Sci. 2015, 38:  796-803.

[36] LP Tang, YQ Wang, TD Leng, HH Sun, YH Zhou, WB Zhu, PX Qiu, JX Zhang, BZ Lu, M Yan, WL Chen, XW Su, W Yin, YJ Huang, HY Hu*, GM Yan*, Cholesterol metabolite cholestane-3β,5α,6β-triol suppresses epileptic seizures by negative modulation of voltage-gated sodium channels. Steroids. 2015, 98: 166-172.

[37] SN Fu#, YQ Xie#, J Tuo, YL Wang, WB Zhu, SH Wu, GM Yan, HY Hu*, Discovery of mitochondria-targeting berberine derivatives as the inhibitors of proliferation, invasion and migration against rat C6 and human U87 glioma cells. MedChemComm. 2015, 6: 164-173.

[38] YZ Chen#, J Tuo#, HZ Huang, D Liu, XH You, JL Mai, JQ Song, YQ Xie, CB Wu, HY Hu*, Optimized mixed oils remarkably reduce the amount of surfactants in microemulsions without affecting oral bioavailability of ibuprofen by simultaneously enlarging microemulsion areas and enhancing drug solubility. Int J Pharmaceut. 2015, 487: 17-24.

[39] J Cai#, HZ Huang#, WJ Song, HY Hu*, JS Chen, LY Zhang, PY Li, R Wu, CB Wu, Preparation and evaluation of lipid polymer nanoparticles for eradicating H. pylori biofilm and impairing antibacterial resistance in vitro. Int J Pharmaceut. 2015, 495: 728-737.

[40] XH You, Q Xing, J Tuo, WJ Song, Y Zeng, HY Hu*, Optimizing surfactant content to improve oral bioavailability of ibuprofen in microemulsions: Just enough or more than enough?. Int J Pharmaceut. 2014, 471: 276-284.

[41] WJ Song, YL Wang, LY Zhang, SN Fu, Y Zeng, HY Hu*, Preparation and evaluation of polysaccharide sulfates for inhibiting Helicobacter pylori adhesion. Carbohyd Polym. 2014, 103: 398-404.

[42] YQ Ou, XK Zheng, YX Gao, MF Shu, TD Leng, Y Li, W Yin, WB Zhu, YJ Huang, YX Zhou, JJ Tang, PX Qiu, GM Yan, J Hu*, HZ Ruan*, HY Hu*, Activation of cyclic AMP/PKA pathway inhibits bladder cancer cell invasion by targeting MAP4-dependent microtubule dynamics. Urol Oncol-Semin Ori. 2014, 32: 47.e21-47.e28.

[43] Y Li, JQ Song, N Tian, J Cai, MH Huang, Q Xing, YL Wang, CB Wu, HY Hu*, Improving oral bioavailability of metformin hydrochloride using water-in-oil microemulsions and analysis of phase behavior after dilution. Int J Pharmaceut. 2014, 473: 316-325.

[44] L Li, J Tuo, YQ Xie, MH Huang, M Huang, RB Pi, HY Hu*, Preparation, transportation mechanisms and brain-targeting evaluation in vivo of a chemical delivery system exploiting the blood-cerebrospinal fluid barrier. J Drug Target. 2014, 22: 724-731.

[45] HY Hu#, YH Zhou#, TD Leng#, AL Liu, YQ Wang, XH You, JK Chen, LP Tang, WL Chen, PX Qiu, W Yin, YJ Huang, JX Zhang, LW Wang, HF Sang, GM Yan, The major cholesterol metabolite cholestane-3β,5α,6β-triol functions as an endogenous neuroprotectant. J Neurosci. 2014, 34: 11426-11438.

[46] SJ Zheng#, YQ Xie#, Y Li, L Li, N Tian, WB Zhu, GM Yan, CB Wu*, HY Hu*, Development of high drug-loading nanomicelles targeting steroids to the brain. Int J Nanomed. 2013, 9: 55-66.

[47] HY Hu, Y Huang, J Liu, XL Xu, T Gong, D Xiang, ZR Zhang, Medium-chain triglycerides based oil-in-water microemulsions for intravenous administration: Formulation, characterization and in vitro hemolytic activities. J Drug Deliv Sci Tec. 2008, 18: 101-107.

发明专利

[1] 胡海燕，张雪飞，李姝璇，董雅婷. 一种防脱生发的脂质体及其制备方法与应用.中国发明专利，专利号ZL202210577332.0，授权日期2024.04.02

[2] 胡海燕，邹祎晴，陈小楠，王亚龙，李彭宇，饶义琴，孙莹莹. 双胍衍生物及其应用与制剂.中国发明专利，专利号ZL202110414905.3，授权日期2023.03.28

[3] 胡海燕，陈小楠，邹祎晴，李彭宇，饶义琴. 一种用于治疗由幽门螺杆菌引起的疾病的囊泡.中国发明专利，专利号ZL202010644981.9，授权日期2023.01.13

[4] 胡海燕，申元娜，邹祎晴，李彭宇，陈小楠，饶义琴. 基于小檗碱衍生物及鼠李糖脂的抗菌纳米粒.中国发明专利，专利号ZL201910436175.X，授权日期2022.05.27

[5] 胡海燕，郭琴，杨绚，倪小敏，丁青，章溢，申元娜，林楚楚. pH敏感型熊胆眼用即型凝胶.中国发明专利，专利号ZL201710380150.3，授权日期2021.08.10

[6] 王军，林永成，胡海燕，陈慧萍. 一种环草石斛提取物及其抗糖尿病用途.中国发明专利，专利号ZL201710013103.5，授权日期2021.03.10

[7] 胡海燕，庹珏，王亚龙，谢彦奇，付胜楠，颜光美，银巍. 小檗碱衍生物及其用途. 中国发明专利，专利号ZL201310218566.7，授权日期 2016.8.10

[8] 胡海燕，付胜楠, 庹珏，谢彦奇，张国光，王亚龙，朱文博. 小檗碱衍生物的医药用途. 中国发明专利，专利号ZL201310218544.0，授权日期 2016.8.31

[9] 胡海燕，宋玮娟，付胜楠，曾颖. 聚半乳糖醛酸硫酸酯在制备抗幽门螺旋杆菌药物中的应用. 中国发明专利，专利号ZL201110437407.7，授权日期 2014.10.1

[10] 胡海燕，蔡婕，王亚龙，王亚娜，林穗珍，石海涛. 5α-雄甾-3β,5,6β-三醇注射剂及其制备方法.中国发明专利，专利号ZL 2013 1 0206207.X，授权日期2015.3.26

[11] 颜光美，胡海燕，冷田东，桑韩飞，张静夏，邱鹏新，周树佳，陈婕思，游秀华. 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用。 中国（专利号ZL201010224173.3，授权日期2011.8.24）, 美国（专利号8,809,309，授权日期2014.8.19）新加坡（专利号201208868-8，授权日期2014.2.14），加拿大（专利号2,802,133，授权日期2014. 1.14），澳大利亚（专利号2,011,276,800，授权日期2014.3.8），日本（专利号5681931，授权日期2015.1.23），韩国（专利号10‐1463477，授权日期2014.11.13），俄罗斯（专利号2541093，授权日期2014.12.24）

[12] 颜光美，胡海燕，张静夏，邱鹏新，李玲，田宁. 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法。 中国(专利号ZL201010292234.X，授权日期2012.11.21), 澳大利亚（专利号2011304917，授权日期2015.2.5），日本（专利号5750680，授权日期2015.5.29），韩国（专利号10-1468153，授权日期2014.11.25），俄罗斯（专利号2532354，授权日期2014.9.5）。

[13] 颜光美，胡海燕，孙环环，桑韩飞，冷田东，刘爱伶，银巍，黄奕俊，张静夏，邱鹏新。胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用. 中国发明专利，专利号ZL200810198703.4，授权日期 2012.7.4.